Abstract: A genetic polymorphism associated with myocardial infarction is provided. More particularly, provided are a polynucleotide including a single nucleotide polymorphism (SNP) or a haplotype associated with myocardial infarction, a polynucleotide hybridized with the polynucleotide, a polypeptide encoded by one of the polynucleotides, an antibody bound to the polypeptide, a microarray and a kit including one of the polynucleotides, a myocardial infarction diagnosis method, a SNP detecting method and a method of screening pharmaceutical compositions for myocardial infarction.

Abstract: Provided is a substrate that is used to produce a microarray, wherein the substrate includes; a fiducial mark disposed on the substrate, and a probe immobilization region disposed on the substrate, wherein a surface of the first fiducial mark is a hydrophobic and a probe immobilization compound is immobilized on the probe immobilization region.

Abstract: Provided are a method and apparatus for selecting pharmacogenomic markers. The method includes calculating evaluation indexes for evaluating the degree of association between genetic markers of genes associated with at least one drug and the drug, and selecting some of the genetic markers based on the calculated evaluation indexes.

Abstract: Provided are a method of analyzing a sequence of a first probe nucleic acid using a substrate on which a second probe nucleic acid is immobilized, and a microarray and a kit for the same.

Abstract: Provided are a method and an apparatus for managing data indicating personal genome data. The method includes obtaining property information of a first personal genome data, which indicates genome information of an individual, by analyzing a first personal genome data, and generating integrated data by integrating the first personal genome data and a second personal genome data indicating genome data of the individual based on the obtained property information.

Abstract: A multiple single nucleotide polymorphism (multi-SNP) marker for cardiovascular disease diagnosis and a method of diagnosing cardiovascular disease are provided. Also, sets of polynucleotides, a microarray, and a kit including the microarray are provided.

Abstract: Provided is a polynucleotide including at least 10 contiguous nucleotides of a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NOS: 1-12 and including a nucleotide at position 101 of the nucleotide sequence, or a complementary polynucleotide thereof.

Abstract: A method of designing primer and probe sets for identification of target sequences by amplification and hybridization is provided. Also, primer and probe sets designed by the method, a kit comprising the sets, a computer readable medium recorded thereon a program to execute the method, and a method of identifying target sequences using the sets are provided. Accordingly, primer and probe sets capable of identifying rapidly and accurately a number of target sequences can be readily designed.

Abstract: A method of detecting a presence of bio-molecules, or a concentration of the target bio-molecules using a field effect transistor, includes allowing a first sample including a first target bio-molecule to contact a sensing surface of the field effect transistor and measuring a change in an electric signal of the field effect transistor, the field effect transistor including a substrate, a source region and a drain region, the source region and the drain region formed apart from each other on the substrate, the source region and the drain region each doped to having an opposite polarity than a polarity of the substrate, a channel region disposed between the source region and the drain region and an insulating layer including the sensing surface, the insulating layer disposed on the channel region.

Abstract: Provided is a polynucleotide including at least 10 contiguous nucleotides of a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NOS: 1-12 and including a nucleotide at position 101 of the nucleotide sequence, or a complementary polynucleotide thereof.

Abstract: Provided is a polynucleotide for diagnosis or treatment of type II diabetes mellitus, including at least 10 contiguous nucleotides of a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NOS: 1-80 and including a nucleotide at position 101 of the nucleotide sequence, or a complementary polynucleotide thereof.

Abstract: Provided is a method of selecting an optimized SNP marker set from a plurality of SNP markers. The method includes selecting an SNP marker set having a high association from a plurality of SNP markers using set-association, selecting SNP markers having a high association by performing discrimination analysis on arbitrary combinations of the markers included in the SNP marker set, and selecting an optimized SNP marker combination satisfying predetermined selection criteria by using receiver operating characteristics (ROC) curve analysis of arbitrary combinations of the selected SNP markers.

Abstract: Provided is a method of predicting risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, the method including: obtaining a biological sample from a lung cancer patient; measuring an expression level of at least one marker gene from the biological sample, the marker gene being selected from the group consisting of marker genes of Table 1, 2 or 3, to obtain data for the expression level of the marker gene; and determining whether the expression level of the marker gene corresponds to an expression level of a recurrence group or an expression level of a non-recurrence group.

Abstract: Provided are an apparatus and a method for coding genetic information. An aligning unit aligns sample genetic information, wild-type probe genetic information, and mutant-type probe genetic information, based on a mutation position. A code storage unit stores first orthogonal codes assigned to each of bases located at left and right base regions based on the mutation position and second orthogonal codes assigned to a base located at the mutation position. A coding unit creates first code strings and second code strings.

Abstract: Provided is a method of predicting risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, the method including: obtaining a biological sample from a lung cancer patient; measuring an expression level of at least one marker gene from the biological sample, the marker gene being selected from the group consisting of marker genes of Table 1, 2 or 3, to obtain data for the expression level of the marker gene; and determining whether the expression level of the marker gene corresponds to an expression level of a recurrence group or an expression level of a non-recurrence group.

Abstract: Provided is a multiple single nucleotide polymorphism (SNP) for colorectal cancer diagnosis, a microarray and a kit including a polynucleotide having the SNP, and a method of diagnosing colorectal cancer using the SNP. Early diagnosis of incidence or possibility of colorectal cancer can be effectively performed by using the method.

Abstract: Disclosed are a forward discrete/inverse-discrete Fourier transform device and method for optical orthogonal frequency division multiplexing (OFDM) communication and a transmitting and receiving apparatus.The forward inverse-discrete Fourier transform device includes N 1:N splitters for splitting subcarrier signals received from N inputs corresponding to the number of optical frequencies of subcarriers, a phase shift delay array module for shifting phases of the split signals from the 1:N splitters, N N:1 power couplers for coupling signals output from the phase shift delay array module, a time delay array module for performing time delay on optical OFDM symbols from the N:1 power couplers, and an N:1 power coupler for coupling signals output from the time delay array module.

Abstract: Provided is a Field-Effect Transistor (FET)-based biosensor including: a substrate; a source and a drain, disposed on the substrate, having opposite polarity to the substrate; a gate, disposed on the substrate, contacting the source and the drain; and an inorganic film capable of binding with a biomolecule, disposed on a surface of the gate. A method of manufacturing the FET-based biosensor and a method of detecting a biomolecule using the FET-based biosensor is also provided. The FET-based biosensor can be manufactured using a semiconductor fabrication process without performing an additional process. Therefore, the inorganic film can be selectively deposited on a surface of a specific gate of a single FET, or on the surfaces of some gates of a plurality of FETs using patterning. Furthermore, the FET-based biosensor can be used to effectively detect trace amounts of a target biomolecule in a sample.

Abstract: Provided is a method of predicting risk of lung cancer recurrence in a lung cancer patient or after a patient has lung cancer treatment, the method including: obtaining a biological sample from a lung cancer patient; measuring an expression level of at least one marker gene from the biological sample, the marker gene being selected from the group consisting of marker genes of Table 1, 2 or 3, to obtain data for the expression level of the marker gene; and determining whether the expression level of the marker gene corresponds to an expression level of a recurrence group or an expression level of a non-recurrence group.

Abstract: Provided is a method of purifying a target substance using silver nanoparticles. The method includes: mixing a sample containing molecules having a thiol group with the silver nanoparticles to obtain a complex of the molecules having the thiol group with the silver nanoparticles; and isolating and removing the complex from the mixture. By using the purification method, PCR amplifiable DNAs can be rapidly purified, and thus, the method can be very efficiently applied to lab-on-chip (LOC).